
NEWSLETTER ON GLOBAL CLINICAL TRIALS

Volume 3, October 2022 (second half)

**Industry Insights for:
Biotech, Pharma, MedTech, Medical Device**



Our biweekly clinical trial newsletter can help you quickly identify new important trials and important conditions.

For more detailed information or more specific business intelligence analysis, please contact us at contact@buttontech.us

Table of Contents

1	SIGNIFICANT CLINICAL TRIALS BY DURATION	1
2	SIGNIFICANT CLINICAL TRIALS BY ENROLLMENT	2
3	CONTACT US FOR CUSTOMIZED BUSINESS INTELLIGENCE ANALYSIS	4

The big data platform built by BUTTON covers business intelligence, clinical data, regulatory information and supply chain data in Biotech/MedTech/Medical Device industry.

In this newsletter, we want to give you a glimpse of some features and insights about BUTTON's database on global clinical trials, which can be accessible in a more comprehensive manner on our platform. Herein, you can browse and get a quick understanding on the issues mentioned above – just as an iceberg, the most important dimensions are below the surface. If you get interested and want to grasp more details, information and data, please contact us at contact@buttontech.us.

1 Significant Clinical Trials by Duration


Generally speaking, a clinical trial with a longer duration may bring more business opportunities to other companies, such as CROs.

Table 1 shows **the expected durations of clinical trials** initiated between October 16^h and 31st 2022, ranked in descending order. Figure 1 shows **the average expected durations by indications** for these clinical trials, ranked in descending order.

**Table 1: Significant Clinical Trials by Expected Durations
(Initiated between 10/16/2022-10/31/2022)**

Title	Phase	Indication	Duration(years)
Immediate Curative vs Conservative Treatment in Older Men With M0	Phase 3	Prostate Cancer	14.2
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Oza	Phase 2/Phase 3	Crohn Disease	9.4
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patient	Phase 3	Oropharyngeal Cancer	8.8
A Randomized Trial of Five Fraction Partial Breast Irradiation	Phase 3	Cosmetic Outcome	8.8
A Randomized Trial of Five Fraction Partial Breast Irradiation	Phase 3	Radiotherapy	8.8
A Randomized Trial of Five Fraction Partial Breast Irradiation	Phase 3	Breast Neoplasm Female	8.8
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) V	Phase 3	Hodgkin Lymphoma	8.7
A Study to Compare Teclistamab in Combination With Daratumumab	Phase 3	Multiple Myeloma	8.7
Tislelizumab Combined With Chemotherapy Followed by Surgery Ver	Phase 3	Head and Neck Squamous Cell Carcinomas	8
Therapeutics in Active Prostate Cancer Surveillance (TAPS02)	Phase 3	Prostate Cancer	8
DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients Wit	Phase 3	Low-grade Glioma	7.3
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus	Phase 3	Newly Diagnosed Multiple Myeloma	6.5
Revascularization Strategy of Multivessel Disease for Patients With A	Phase 4	Acute Myocardial Infarction	6.2
Revascularization Strategy of Multivessel Disease for Patients With A	Phase 4	Cardiogenic Shock	6.2
Revascularization Strategy of Multivessel Disease for Patients With A	Phase 4	Extracorporeal Membrane Oxygenation	6.2

**Figure 1: Significant Indications by Average Expected Durations
(Initiated between 10/16/2022-10/31/2022)**



Our database shows that, for the clinical trials that were initiated in the second half of October 2022, the average duration is longest for clinical trials in Prostate Cancer (14.2 years), Crohn Disease (9.4 years). Other indications such as Oropharyngeal Cancer, Cosmetic Outcome, Radiotherapy and Breast Neoplasm Female are expected to take approximately 8.8 years, respectively.

If you would like to know more comprehensive lists of indications, clinical trials and sponsors, please contact us at contact@buttontech.us.

2 Significant Clinical Trials by Enrollment


Generally speaking, a clinical trial with more enrollments may bring more business opportunities to other companies, such as CROs.

Table 2 shows **the enrollments of clinical trials** (all in Phase 4) initiated between October 16th and 31st 2022, ranked in descending order. Figure 2 shows **the total enrollments by indications** for these clinical trials, ranked in descending order.

**Table 2: Significant Clinical Trials by Enrollments
(Initiated between 10/16/2022-10/31/2022)**

Title	Phase	Indication	Enrollment
Trial to Compare BCG-Bulgaria and BCG-Denmark	Phase 4	Non-specific Effects of Vaccines	15,000
Trial to Compare BCG-Bulgaria and BCG-Denmark	Phase 4	Death Neonatal	15,000
Trial to Compare BCG-Bulgaria and BCG-Denmark	Phase 4	Death, Infant	15,000
Trial to Compare BCG-Bulgaria and BCG-Denmark	Phase 4	Morbidity, Newborn	15,000
Trial to Compare BCG-Bulgaria and BCG-Denmark	Phase 4	Morbidity, Infant	15,000
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infar	Phase 4	Cardiovascular Disease	4,000
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infar	Phase 4	Coronary Revascularization	4,000
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infar	Phase 4	Stroke	4,000
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infar	Phase 4	Myocardial Infarction	4,000
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy	Phase 4	Coronary Artery Bypass Grafting	2,300
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy	Phase 4	Bleeding	2,300
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy	Phase 4	Myocardial Infarction	2,300
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy	Phase 4	Myocardial Ischemia	2,300
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy	Phase 4	Angina Pectoris	2,300
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy	Phase 4	Coronary Artery Disease	2,300

**Figure 2: Significant Indications by Total Enrollments
(Initiated between 10/16/2022-10/31/2022)**





For the second half of this past October (2022.10), it seems like the clinical trials are putting on a strong emphasis and focus on neonatal health and cardiovascular indications. By enrollment, a majority of the clinical trials revolve around indications in those two areas, such as infant morbidity/death, stroke, coronary revascularization etc.

3 Contact Us for Customized Business Intelligence Analysis

Please contact us at contact@buttontech.us if you are interested in getting to know about latest clinical trials in more details, such as:

- **Active PIs;**
- **Active sponsors;**
- **Latest clinical trials for particular enrollment sizes, durations, indications, and eligibility criteria;**
- **Leading clinical experts in a particular field/area;**
- **Other customized business intelligence analysis for clinical trials.**

Powered by BUTTON Platform

2672 Bayshore Parkway, Suite 1001, Mountain View, CA 94043

WEB: <https://www.button-corp.com> EMAIL: contact@buttontech.us